Role of gabapentin and anticholinergics in management of neurogenic bladder after repair of spina bifida - a randomized controlled study

J Pediatr Surg. 2016 Dec;51(12):2025-2029. doi: 10.1016/j.jpedsurg.2016.09.030. Epub 2016 Sep 15.

Abstract

Background: Anticholinergics are well established in the management of neurogenic bladders. However, some patients do have sub-optimal response or severe side effects. This study is designed to assess and compare efficacy of gabapentin with oxybutynin in neurogenic bladders after surgery for spina bifida.

Methods: Patients were randomized into three groups after urodynamic studies and started on oxybutynin, gabapentin, and combination of both, respectively. Thorough clinical and urodynamic reassessment was done at 6months and one year after starting treatment.

Results: Forty-four patients (3-19years) were studied. Improvement was noted in symptoms as well as urodynamic parameters in all groups. Maximal improvement of symptom score was with combination of drugs at 1year. In urodynamic studies, compliance, pressures, and capacity showed improvement, which was significant between the groups at both six months and 1year for bladder pressures and volume. Improvement in compliance though marked was not statistically significant. Best response was seen in group receiving both drugs. Gabapentin was better tolerated than oxybutynin.

Conclusion: Gabapentin is a good alternative to oxybutynin for management of neurogenic bladder, both as monotherapy and as an add-on therapy. It has potential application in patients with inadequate response to anticholinergics.

Level of evidence: prospective competitive treatment study - level II.

Keywords: Anticholinergics; Clean intermittent catheterization; Gabapentin; Neurogenic bladder; Spina bifida; Urodynamics.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Amines / therapeutic use*
  • Child
  • Child, Preschool
  • Cholinergic Antagonists / therapeutic use
  • Cyclohexanecarboxylic Acids / therapeutic use*
  • Female
  • Gabapentin
  • Humans
  • Male
  • Mandelic Acids / therapeutic use*
  • Prospective Studies
  • Spinal Dysraphism / complications
  • Spinal Dysraphism / surgery*
  • Urinary Bladder, Neurogenic / drug therapy*
  • Urinary Bladder, Neurogenic / etiology
  • Urological Agents / therapeutic use*
  • Young Adult
  • gamma-Aminobutyric Acid / therapeutic use*

Substances

  • Amines
  • Cholinergic Antagonists
  • Cyclohexanecarboxylic Acids
  • Mandelic Acids
  • Urological Agents
  • gamma-Aminobutyric Acid
  • Gabapentin
  • oxybutynin